Definition
A racemic mixture (or racemate) is a 50:50 combination of two mirror-image forms of the same molecule, known as enantiomers. In the case of ketamine, the racemic mixture contains equal parts S-ketamine (esketamine) and R-ketamine (arketamine). Most ketamine used in clinical settings — whether administered intravenously, orally, or as a troche — is racemic ketamine, meaning it contains both enantiomers. The FDA-approved nasal spray product, by contrast, contains only the S-enantiomer.
Understanding Enantiomers
Many drug molecules are chiral, meaning they exist in two structural forms that are non-superimposable mirror images of each other — like a left hand and a right hand. These two forms are called enantiomers and are designated by their stereochemical configuration. In ketamine, the two enantiomers are named S(+)-ketamine and R(-)-ketamine based on the spatial arrangement of atoms around a single chiral carbon center.
Although enantiomers have identical chemical formulas and physical properties (such as molecular weight and melting point), they can interact very differently with biological targets. Receptors, enzymes, and transport proteins in the body are themselves chiral structures, so they often distinguish between the two mirror-image forms of a drug, binding one more tightly than the other.
S-Ketamine vs R-Ketamine
S-ketamine (esketamine) has approximately three to four times greater binding affinity for the NMDA receptor compared to R-ketamine. It is also a more potent anesthetic and produces stronger dissociative effects at equivalent doses. Because of this higher potency, lower doses of esketamine are needed to achieve the same level of NMDA receptor blockade. The FDA approved esketamine as a nasal spray in 2019 specifically for treatment-resistant depression.
R-ketamine (arketamine) has weaker NMDA receptor affinity but has generated significant research interest due to preclinical findings suggesting it may produce longer-lasting antidepressant effects with fewer dissociative side effects. Animal studies have indicated that R-ketamine more potently activates BDNF signaling and promotes synaptogenesis through mechanisms that may be partially independent of NMDA receptor blockade. Several clinical trials of R-ketamine for depression are underway as of 2025.
Why the Racemic Mixture Matters
The distinction between racemic ketamine and its individual enantiomers has significant clinical and regulatory implications:
Pharmacological profile: The racemic mixture delivers the combined effects of both enantiomers simultaneously. Some researchers and clinicians believe this combination produces a more balanced therapeutic profile — with S-ketamine contributing more acute NMDA blockade and dissociation, while R-ketamine may contribute to sustained neuroplasticity and mood improvement with a gentler subjective experience.
Regulatory status: Racemic ketamine is a generic drug that has been available since 1970 and can be prescribed off-label for depression. Esketamine, as a patented single-enantiomer product, went through the full FDA approval process and carries a specific indication for TRD. This distinction affects insurance coverage, cost, and prescribing requirements.
Cost considerations: Generic racemic ketamine is substantially less expensive than branded esketamine. Racemic ketamine from compounding pharmacies may cost a fraction of the price of the branded nasal spray, making it more accessible to many patients.
Research implications: Head-to-head comparisons between racemic ketamine, S-ketamine, and R-ketamine are an active area of clinical investigation. Understanding which enantiomer (or combination) produces the best balance of efficacy, duration, and tolerability could refine treatment protocols and improve patient outcomes.
Clinical Context
In current practice, clinicians may choose between racemic ketamine (available as generic IV formulations or compounded oral preparations) and esketamine (the branded nasal spray). The choice often depends on clinical setting, insurance coverage, patient preference, and individual response. Neither form has been definitively proven superior to the other for depression treatment, though the available evidence base is larger for racemic IV ketamine.
References
- Comparative Pharmacology of Ketamine Enantiomers — Zanos et al. (2018), Pharmacological Reviews. Comprehensive review of enantiomer pharmacology.
- R-Ketamine Antidepressant Effects in Preclinical Models — Yang et al. (2015), Translational Psychiatry. Evidence for R-ketamine's distinct mechanism.
- FDA Esketamine Approval Information — FDA press announcement on esketamine nasal spray.
Share